Anixa Biosciences Inc (ANIX)

Name: Anixa Biosciences Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-01-31

Latest Quarter

2026-01-31

Revenue

$0.0

Net Income

-$2.6M

Operating Margin

N/A

Free Cash Flow

-$7.2M

Debt / Assets

13.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Anixa Biosciences Inc (ANIX).
Income Statement (Quarterly)	2026-01-31	2025-04-30	2025-01-31	2024-10-31
Revenue	0	0	0	0
Cost of Revenue	10,000	0	0	0
Gross Profit	-10,000	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	1,614,000	1,681,000	1,834,000	1,687,000
Operating Expenses	2,716,000	3,003,000	3,386,000	3,163,000
Operating Income	-2,716,000	-3,003,000	-3,386,000	-3,163,000
Interest Expense	0	0	0	0
Income Before Tax	-2,585,000	-2,813,000	-3,213,000	-2,913,000
Income Tax Expense	0	0	0	0
Net Income	-2,565,000	-2,790,000	-3,184,000	-2,883,000
Per Share
EPS	-0.08	-0.09	-0.10	0.30
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Anixa Biosciences Inc (ANIX).
Income Statement (Annual)	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31
Revenue	0	0	210,000	2,469,000,000	512,500
Cost of Revenue	36,000	0	161,000	42,000	385,002
Gross Profit	-36,000	0	49,000	2,468,958,000	127,498
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	6,630,000	7,435,000	6,291,000	7,172,000	7,073,498
Operating Expenses	11,665,000	13,831,000	11,060,000	13,875,000	13,263,190
Operating Income	-11,701,000	-13,831,000	-11,011,000	-13,875,000	-13,135,692
Interest Expense	0	0	0	104,000	0
Income Before Tax	-11,028,000	-12,698,000	-9,930,000	-13,771,000	-13,127,923
Income Tax Expense	0	0	0	-280,000	0
Net Income	-10,927,000	-12,554,000	-9,811,000	-13,491,000	-12,954,400
Per Share
EPS	-0.34	-0.39	-0.32	-0.44	-0.45
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Anixa Biosciences Inc (ANIX).
Balance Sheet (Quarterly)	2025-10-31	2024-10-31	2023-10-31	2022-10-31
Assets
Cash and Cash Equivalents	1,244,000	1,271,000	915,000	12,360,000
Short Term Investments	13,930,000	18,653,000	22,929,000	17,327,000
Net Receivables	0	173,000	270,000	46,000
Inventory	0	0	0	-46,000
Total Current Assets	15,887,000	21,362,000	25,356,000	30,200,000
Property Plant Equipment	193,000	229,000	166,000	212,000
Goodwill and Intangibles	0	0	0	0
Total Assets	16,080,000	21,591,000	25,522,000	30,412,000
Liabilities
Account Payables	165,000	525,000	206,000	265,000
Short Term Debt	41,000	29,000	104,000	46,000
Total Current Liabilities	1,967,000	2,500,000	2,028,000	2,037,000
Long Term Debt	163,000	203,000	123,000	175,000
Total Liabilities	2,130,000	2,703,000	2,151,000	2,212,000
Shareholders Equity
Retained Earnings	-251,677,000	-240,750,000	-228,196,000	-218,385,000
Total Shareholders Equity	15,161,000	19,998,000	24,337,000	29,047,000

Balance sheet annual history for Anixa Biosciences Inc (ANIX).
Balance Sheet (Annual)	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31
Assets
Cash and Cash Equivalents	1,244,000	1,271,000	915,000	12,360,000	29,128,298
Short Term Investments	13,930,000	18,653,000	22,929,000	17,327,000	6,599,595
Net Receivables	0	173,000	270,000	46,000	0
Inventory	0	0	0	-46,000	0
Total Current Assets	15,887,000	21,362,000	25,356,000	30,200,000	36,003,449
Property Plant Equipment	193,000	229,000	166,000	212,000	253,955
Goodwill and Intangibles	0	0	0	0	0
Total Assets	16,080,000	21,591,000	25,522,000	30,412,000	36,257,404
Liabilities
Account Payables	165,000	525,000	206,000	265,000	136,196
Short Term Debt	41,000	29,000	104,000	46,000	39,397
Total Current Liabilities	1,967,000	2,500,000	2,028,000	2,037,000	1,270,528
Long Term Debt	163,000	203,000	123,000	175,000	220,082
Total Liabilities	2,130,000	2,703,000	2,151,000	2,212,000	1,490,610
Shareholders Equity
Retained Earnings	-251,677,000	-240,750,000	-228,196,000	-218,385,000	-204,790,018
Total Shareholders Equity	15,161,000	19,998,000	24,337,000	29,047,000	35,437,300

Cash flow quarterly history for Anixa Biosciences Inc (ANIX).
Cash Flow Statement (Quarterly)	2025-10-31	2024-10-31	2023-10-31	2022-10-31
Operating Activities
Net Income	-11,028,000	-12,698,000	-9,930,000	-13,771,000
Depreciation & Amortization	-107,000	37,000	46,000	42,000
Stock Based Compensation	3,681,000	4,420,000	4,827,000	6,000,000
Change in Working Capital	152,000	526,000	-1,060,000	485,000
Operating Cash Flow	-7,173,000	-7,335,000	-6,209,000	-6,492,000
Investing Activities
Capital Expenditure	0	0	0	0
Investments	0	0	0	0
Investing Cash Flow	4,866,000	4,276,000	-5,602,000	-10,728,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	2,280,000	2,949,000	92,000	97,000
Dividends Paid	0	0	0	0
Financing Cash Flow	2,280,000	3,415,000	366,000	452,000
Summary
Free Cash Flow	-7,173,000	-7,335,000	-6,209,000	-6,492,000
Net Change in Cash	-27,000	356,000	-11,445,000	-16,768,000

Cash flow annual history for Anixa Biosciences Inc (ANIX).
Cash Flow Statement (Annual)	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31
Operating Activities
Net Income	-11,028,000	-12,698,000	-9,930,000	-13,771,000	-12,954,400
Depreciation & Amortization	-107,000	37,000	46,000	42,000	59,864
Stock Based Compensation	3,681,000	4,420,000	4,827,000	6,000,000	8,058,078
Change in Working Capital	152,000	526,000	-1,060,000	485,000	78,547
Operating Cash Flow	-7,173,000	-7,335,000	-6,209,000	-6,492,000	-4,936,881
Investing Activities
Capital Expenditure	0	0	0	0	0
Investments	0	0	0	0	0
Investing Cash Flow	4,866,000	4,276,000	-5,602,000	-10,728,000	-3,917,675
Financing Activities
Debt Repayment	0	0	0	0	0
Common Stock Issued/Repurchased	2,280,000	2,949,000	92,000	97,000	31,125,569
Dividends Paid	0	0	0	0	0
Financing Cash Flow	2,280,000	3,415,000	366,000	452,000	31,565,793
Summary
Free Cash Flow	-7,173,000	-7,335,000	-6,209,000	-6,492,000	-4,936,881
Net Change in Cash	-27,000	356,000	-11,445,000	-16,768,000	22,711,237